Dose Escalation & Expansion Study of Oral VRx-3996 & Valganciclovir in Subjects With EBV-Associated Lymphoid Malignancies
Epstein-Barr Virus Associated Lymphoma Lymphoproliferative Disorders EBV+ post-transplant lymphoproliferative malignancy EBV-associated lymphoproliferative disorders associated with acquired immunodeficiency Relapsed, refractory, EBV+ lymphoid malignancy Neoplasms Valganciclovir VRx-3996
Lead Scientist at UC Cancer
- Elizabeth Brem, MD (uci)
Assistant Health Sciences Professor, Medicine. Authored (or co-authored) 8 research publications.